June is Awareness of Alzheimer’s and brain awareness.
Promise Research Warning!
If you are watching any TV or any screen, you probably have heard about the peptide-1 (GLP-1) that look like glucagon or GLP-1 drugs. Popular weight loss drugs help manage blood sugar and reduce appetite in people who live with type 2 diabetes and obesity.
GLP-1 medicines have also been associated Reduced risk of cardiovascular events, kidney events and kidney failure. Now, researchers hope to add Alzheimer to the list.
A recent study He found that the GLP-1 semaglutide (which you may know as Ozempic and Wegovy) can slow down Alzheimer’s growth or even prevent the situation in people with type 2 diabetes.
“This is an important conclusion, especially because it was based on actual health files from over a million people,” he said Babak Tousi, MDClinical trial director at the Lou Ruvo Center for Cleveland’s brain health in Cleveland in Cleveland in Cleveland.
The study found that people with type 2 diabetes who took the semiaglitis were significantly less likely-40% to 70%-to be diagnosed with Alzheimer’s within three years compared to people taking other diabetes drugs, including other GLP-1 drugs.
“It indicates that semaglutide can do more than blood sugar control – it can provide real brain protection,” Tousi said.
Read: The skinny for microdosing GLP-1 drugs >>
How hemiaglutide affects brain health
Research continues with regard to the effect of semicglitis on the brain – and most studies include animals so far – but an increasing set of research shows that semiagliditis can benefit cognitive function in people with diabetes and/or obesity through improved memory, learning and learning.
Systematic review He found that hemiaglutide protects the blood -brain barrier, which is responsible for the discontinuation of toxins, pathogens (causing illness) and other harmful substances from leakage to the brain.
“The semiaglidal can calm the brain inflammation, especially in the immune cells of the brain called microgly, and help protect the blood-brain barrier-which acts as a security guard for the brain,” Tousi said. “It also seems to improve blood flow, reduce oxidative stress – a type of damage that accumulates in the brain – and supports brain cell function. All these factors play a role in Alzheimer’s disease.”
Other study He found that the semiglidide reverses the signs of aging in basic brain cells that help to keep our brain clean, protected and balanced. “Age can lead to these cells that act on, causing inflammation of the brain and confusion.
Get the quiz: How much do you know about Alzheimer’s disease? >>
Tousi also noted that the study found that the Imaglutide prevented the formation of an astrocyte type – a brain cell converted toxic under stress – which aggravates inflammation and damages the brain tissue, a procedure also observed in Alzheimer’s disease.
This is similar to the findings of one more studyIt noted that the semiaglitis improved cognitive abilities in mice by performing several functions, one of which reduced the amount of amyloid plates in the brain. Amyloid plates are believed to play a role in Alzheimer’s, and this research suggests that semiaglutide can not only have a role in Alzheimer’s prevention, but can also improve Alzheimer’s in people who already have it.
Semaglutide for people running at risk for Alzheimer’s
Type 2 diabetes and obesity are known risk factors for Alzheimer’s disease. But since recent findings in human studies, semaglutide can be useful for anyone at risk for Alzheimer’s disease.
“Because semiaglutide seems to help reduce inflammation and protect the brain, there is a growing interest in whether it can also benefit people without diabetes, especially those with early memory concerns or a strong family history of dementia,” Tousi said. “This could signal a future where a common diabetes medicine plays a big role in brain health and even prevention of dementia.”
This is particularly important to note that women and people who are assigned women at birth (AFAB), since Alzheimer’s is more common in women than men. About 1 in 5 women will be diagnosed with Alzheimer’s disease during their lifetime compared to 1 in 10 men.
There is currently no cure for Alzheimer’s so that the progress of treatment for the management and prevention of the disease are critical.
Promise new research on the horizon
There is hope on the horizon in terms of semaglutide in the prevention or treatment of Alzheimer’s disease. Its effects First large -scale study The appearance of if semaglutide can slow Alzheimer’s in people with early stages of illness – even in people without type 2 diabetes – will be released in September.
Read: Do you need to get a blood test for Alzheimer’s? >>
Tousi said the study includes a sub-study where the spinal fluid is analyzed to help reveal how the drug works in the brain. The study could provide indications of the exact semaglutide mechanism and guide future treatments.
“It is also worth noting that Alzheimer’s affects women more than men and the first data suggest that the benefits of the Semaglutide brain can be even stronger in women,” Tousi said. “These tests should help to clarify it.”
By the articles of your site
Related articles around the web
